Close Menu

Sciex

For the three months ended July 3, the Washington DC-based conglomerate recorded $5.30 billion in total sales compared to $4.44 billion in the year-ago period.

While there were a few new mass spectrometry instrument introductions, vendors focused primarily on software and sample separation advances.

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.

The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.

While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.

Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.